Danaher nears a roughly $10B deal for Masimo

Welcome back to Breaking News to Trading Moves. Today we’re covering a major medtech M&A headline: Danaher is reportedly closing in on a nearly $10B acquisition of Masimo, a move that could reshape patient-monitoring and ripple across medtech and life sciences tools.

Main news discussion

Danaher is reported to be nearing an acquisition of Masimo valued around $10B, with a possible announcement as early as Tuesday. Masimo is best known for patient-monitoring technology (including pulse oximeters). Masimo’s patent dispute with Apple, including a jury award tied to blood-oxygen reading technology.

Why the market cares

This is a big consolidation signal in medtech. A transaction of this size can re-rate patient-monitoring comps, raise expectations for more de ...